EW vs NAGE: fair value comparison
Edwards Lifesciences Corporation and Niagen Bioscience, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EW currently sits closer to the top of our discount ranking.
| EW | NAGE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $84.37 | $3.13 |
| 12-month range | $81.26–$90.74 | $3.13–$7.89 |
| Sector rank | #45 of 113 Healthcare | #47 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: EW fair value analysis · NAGE fair value analysis